Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07512362 · ClinicalTrials.gov registry record · Phase 2
Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.
A Phase 2 study, sponsored by Bernard (Barry) Baumel.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT07512362 is a Phase 2 study that is actively recruiting participants, run by Bernard (Barry) Baumel. The registered enrollment target is 10 participants.
The verdict
NCT07512362, a Phase 2 study, is actively recruiting participants, sponsored by Bernard (Barry) Baumel.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to test if adding one infusion of (Human Mesenchymal Stem Cells) hMSCs to the treatment with standard of care (SOC) monoclonal antibodies (mAb) will stabilize the rate of cognitive and functional decline associated with mild Alzheimer's Disease.
Interventions
- BIOLOGICAL human Mesenchymal Stem Cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-05-15 |
| Est. Completion | 2028-06-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07512362
The ClinicalTrials.gov registry entry for NCT07512362 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bernard (Barry) Baumel, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which human Mesenchymal Stem Cells is the first listed.
NCT07512362 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07512362 about?
NCT07512362 is a clinical study titled "Human Mesenchymal Stem Cells & Monoclonal Antibodies in the Treatment for Mild Cognitive Impairment or Early Alzheimer's Disease.". The purpose of this study is to test if adding one infusion of (Human Mesenchymal Stem Cells) hMSCs to the treatment with standard of care (SOC) monoclonal antibodies (mAb) will stabilize the rate of cognitive and functional decline associated with mild Alzheimer's Disease.
What is the current status of trial NCT07512362?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2026-05-15. Estimated completion is 2028-06-15.
What interventions are being tested in trial NCT07512362?
The interventions under investigation include: human Mesenchymal Stem Cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT07512362?
This trial is sponsored by Bernard (Barry) Baumel, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.